 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Sunday
NeuroDerm Awarded $490,000 by The Michael J. Fox Foundation to Commence Clinical Studies on a Novel Skin Patch For Parkinson's Disease:
"Neuroderm Ltd.announced today that it has been granted $490,000 in funding by The Michael J. Fox Foundation for Parkinson's Research. The award will support clinical work to develop a new transdermal skin patch for continuous delivery of levodopa, the natural precursor of dopamine, which is deficient in Parkinson's disease.
Continuous dopamine delivery systems have generated a great deal
of interest because it is hypothesized that dyskinesias -- disruptive,
jerky movements associated with long-term levodopa therapy -- result
from the sharp fluctuations in dopamine blood levels that occur when
levodopa is given orally. But to date all attempts at achieving
continuous delivery have proved impractical or infeasible, and
attempts to deliver levodopa transdermally have failed because, among
other reasons, the drug is unstable, insoluble and does not penetrate
the skin. NeuroDerm's innovative system is based on a proprietary
formulation involving a prodrug, levodopa ester (LDE). The company has
demonstrated significant success in maintaining steady therapeutic
levodopa blood levels in animal models.
NeuroDerm believes that the patch, by overcoming the short half
life of levodopa through continuous transdermal delivery, should be
able to minimize or even reverse dyskinesias and other disabling late
motor complications associated with long-term oral levodopa
administration in advanced Parkinson's disease.
'We are delighted that the Foundation has recognized the immense
impact our program may have on the lives of many Parkinson's patients.
I hope that NeuroDerm will be able to offer a practical solution to
patients suffering from damage caused in late-stage Parkinson's
disease and to earlier stage patients wishing to slow down the
development of late motor complications', said Eli Heldman, Ph.D., and
Moshe Kushnir, M.D., founders of NeuroDerm.
'This Clinical Discovery Program grant is part of our focus on
speeding highly relevant treatments to people living with Parkinson's
disease,' said Deborah W. Brooks, president and CEO of The Michael J.
Fox Foundation. 'We believe that improved delivery through continuous
levodopa administration, such as NeuroDerm's prospective patch aims to
achieve, could potentially result in a significant improvement in
patients' day-to-day lives.'....."
"Neuroderm Ltd.announced today that it has been granted $490,000 in funding by The Michael J. Fox Foundation for Parkinson's Research. The award will support clinical work to develop a new transdermal skin patch for continuous delivery of levodopa, the natural precursor of dopamine, which is deficient in Parkinson's disease.
Continuous dopamine delivery systems have generated a great deal
of interest because it is hypothesized that dyskinesias -- disruptive,
jerky movements associated with long-term levodopa therapy -- result
from the sharp fluctuations in dopamine blood levels that occur when
levodopa is given orally. But to date all attempts at achieving
continuous delivery have proved impractical or infeasible, and
attempts to deliver levodopa transdermally have failed because, among
other reasons, the drug is unstable, insoluble and does not penetrate
the skin. NeuroDerm's innovative system is based on a proprietary
formulation involving a prodrug, levodopa ester (LDE). The company has
demonstrated significant success in maintaining steady therapeutic
levodopa blood levels in animal models.
NeuroDerm believes that the patch, by overcoming the short half
life of levodopa through continuous transdermal delivery, should be
able to minimize or even reverse dyskinesias and other disabling late
motor complications associated with long-term oral levodopa
administration in advanced Parkinson's disease.
'We are delighted that the Foundation has recognized the immense
impact our program may have on the lives of many Parkinson's patients.
I hope that NeuroDerm will be able to offer a practical solution to
patients suffering from damage caused in late-stage Parkinson's
disease and to earlier stage patients wishing to slow down the
development of late motor complications', said Eli Heldman, Ph.D., and
Moshe Kushnir, M.D., founders of NeuroDerm.
'This Clinical Discovery Program grant is part of our focus on
speeding highly relevant treatments to people living with Parkinson's
disease,' said Deborah W. Brooks, president and CEO of The Michael J.
Fox Foundation. 'We believe that improved delivery through continuous
levodopa administration, such as NeuroDerm's prospective patch aims to
achieve, could potentially result in a significant improvement in
patients' day-to-day lives.'....."